Adlai Nortye Ltd.

NASDAQ:ANL

Biotechnology

Healthcare
$8.74 -1.07%

-$0.11 today

Market cap
$463.92M
Beta
0.99
P/E (TTM)
-3.0
EPS (TTM)
-$3.33
52W Low $0.88High $17.25

Volume 0.45M

Average 0.35M

ANL Free Cash Flow

Operating cash flow minus capital expenditures: cash available for debt repayment, dividends, and buybacks.

Adlai Nortye Ltd.NASDAQ: ANL

Free Cash Flow · Q2 FY2024 · quarter ended Jun 2024

Free cash flow grows in line with its trailing trend

Q2 FY2024 free cash flow of $14.25M (cash outflow) rose 70.0% year over year, behind the +71.9% change in trailing-twelve-month free cash flow. Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at -8.8% a year.

Context

  • Free cash flow amounted to 674.5% of revenue in FY2025.
  • Free cash flow grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +70.0% toward the trailing-twelve-month pace of +71.9%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2024
-$14.25M+0.0% QoQ
Last fiscal yearDec 2025
-$33.73M-35.1% YoY
LTMJun 2024
-$66.94M+71.9% YoY
Free Cash Flow past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+70.0%——
1 year-35.1%——
3-year CAGR-8.8%——
5-year CAGR——
10-year CAGR——

Free Cash Flow history

USD · from the cash flow

Latest · FY2025
(33.73M) USD
Year-over-year change
+35.1%

Free Cash Flow vs competitors

How ANL compares with its peers on the latest reported figures

  • ANL's LTM Jun 2024 free cash flow of $66.94M is the 4th largest of the 7 companies compared; the peer median is $58.93M.
  • Free cash flow amounts to 1031.4% of revenue for ANL, versus a peer median of 122.0%.
ANL Competitors Peer median
Free Cash Flow for ANL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VSTMVerastem, Inc.LTM Mar 2026$152.29M +32.3%+29.3%307.1%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$87.42M -8.8%—309.7%
NUVBNuvation Bio Inc.LTM Jun 2026$82.72M -50.9%+21.7%48.7%
ANLAdlai Nortye Ltd.LTM Jun 2024$66.94M —-8.8%1031.4%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026$35.14M +23.0%+6.5%—
APLMApollomics, Inc.FY2025$10.37M -64.0%-37.8%122.0%
CGENCompugen Ltd.LTM Dec 2025$0 ——0.0%
Peer median (excluding ANL) $58.93M-8.8%+14.1%122.0%

Competitors are the stored peer set for ANL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(56.68M)(58.79M)(104.87M)(51.87M)(35.62M)
Depreciation & Amortization1.83M2.04M2.22M1.87M1.42M
Deferred Income Tax(67K)(1.04M)000
Stock-Based Compensation3.39M6.08M4.33M2.45M0
Change in Working Capital250K15.25M6.12M(5.54M)(2.29M)
Accounts Receivables00000
Inventory00000
Accounts Payables600K10.12M1.25M(4.2M)2.5M
Other Working Capital(350K)5.13M4.87M(1.34M)(4.79M)
Other Non-Cash Items48.25M(6.76M)35.54M1.27M2.96M
Operating Cash Flow(3.03M)(43.22M)(56.65M)(51.82M)(33.54M)
Capital Expenditures(1.12M)(1.27M)(200K)(170K)(187.49K)
Acquisitions (Net)(102K)(2K)0(4.21M)0
Purchases of Investments(81.23M)(58.98M)(31.83M)(60.55M)(20.49M)
Sales of Investments27.47M88.06M21.02M92.26M5.05M
Other Investing Activities134K569K53.6K734K0
Investing Cash Flow(54.86M)28.38M(10.95M)28.07M(15.62M)
Debt Repayment1.02M(6.49M)25.06M(4.86M)(2.02M)
Common Stock Issued97.37M091.78M152.08K0
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.19M)(292K)(602K)(1.87M)(1.81M)
Financing Cash Flow97.2M(6.78M)116.24M(6.58M)(3.82M)
Effect of Forex Changes561K254K100K(257K)15.87M
Net Change in Cash39.87M(21.37M)48.73M(30.59M)(37.12M)
Free Cash Flow(4.15M)(44.49M)(56.85M)(51.99M)(33.73M)

Adlai Nortye Ltd.

NASDAQ:ANL

Intrinsic Alpha fair value

Locked

Current Price

$8.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.